LLY News and Press, Eli Lilly and Company From 05/03/24

2024-05-03 16:00:00 ET Summary As the wider market turns pessimistic, Eli Lilly continues to trade sideways at these inflated levels with the stock still boasting overly premium valuations, triggering a minimal margin of safety. While LLY's capacity expansions and M&A activiti...

2024-05-03 10:28:54 ET More on Amgen Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Biggest stock movers today: WOW, AAPL, SQ, and more Amge...

2024-05-03 06:12:44 ET Summary Eli Lilly and Company's stock has seen a significant rally due to excitement about its weight loss drug, Zepbound, among other products. It's a healthy, growing business with higher revenues each year, but adjusting for cash outflows from M&A and...

2024-05-02 19:23:00 ET By almost any measure, Eli Lilly (NYSE: LLY) stock has been a standout so far in 2024. Using a basic yardstick, the pharmaceutical sector giant's share price has climbed by over 33%, against the S&P 500 index's 5%. A mix of well-established commerciali...

2024-05-02 17:40:21 ET More on Amgen Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Amgen Non-GAAP EPS of $3.96 beats by $0.05, revenue of $7.45B in-line ...

2024-05-02 15:10:06 ET More on Eli Lilly, Palatin Tech, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise GLP-1 drug pri...

2024-05-02 14:31:50 ET More on Novartis, Novartis AG, etc. Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis AG 2024 Q1 - Results - Earnings Call Presentation Novartis to b...

2024-05-02 09:58:32 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise Novo Nordisk s...

2024-05-02 09:17:44 ET More on Novo Nordisk Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy Novo Nordisk Remains The Better Buy After A Moderate Pullback Novo Nordisk: The Moat Won't Last Forever Novo Nordisk lifts guidance as Ozempic,...

2024-05-02 05:45:00 ET Shares of Eli Lilly and Company (NYSE: LLY) have soared nearly 35% so far in 2024 and are only a few points away from doubling over the last 12 months. The company reigns as the biggest drugmaker in the world based on market cap. It's also the largest company ...